28 Apr 2026 by admin in UncategorizedComments Avenzo Therapeutics Advances the Combination of CDK4 Selective Inhibitor (AVZO-023) with CDK2 Selective Inhibitor (AVZO-021) in Ongoing Phase 1/2 ORION-1 Study in HR+/HER2- Breast Cancer
22 Apr 2026 by admin in UncategorizedComments Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T
14 Apr 2026 by admin in UncategorizedComments Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts
10 Apr 2026 by admin in UncategorizedComments Oricell Therapeutics Closes $110 Million Pre-IPO Financing to Accelerate Global Development of Solid Tumor CAR-T Therapies
07 Apr 2026 by admin in UncategorizedComments NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer
